WuXi PharmaTech (Cayman) Inc. has entered into a definitive agreement and merger plan with new WuXi Life Science Ltd. and WuXi Merger Ltd., a wholly owned subsidiary of Parent.The merger, expected to close during 4Q15, is subject to customary closing conditions.   Parent will acquire the company for approximately $3.3 billion in cash. Following the transaction, Parent will be owned by a consortium comprised of new investors, which include affiliates of or funds managed or advised by Ally Bridg...